FATE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.22 USD | +1.69% |
|
+8.76% | +12.83% |
| 05-10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
| 05-10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FATE THERAPEUTICS, INC. | Bio Therapeutic Drugs | +1.69% | +8.76% | +12.83% | -15.09% | -75.58% | 480M |  |  |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- FATE Stock
- Charts Fate Therapeutics, Inc.
- Comparison Chart
